A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Conditions: B-cell Lymphoma; Non-Hodgkin Lymphoma; B-cell Malignancy; Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL); Follicular Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Large B-cell Lymphoma Intervention: Biological: CTX112 Sponsor: CRISPR Therapeutics AG Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Leukemia | Lymphoma | Research | Study